Radar · Life Sciences in Menlo Park
Best Life Sciences Companies in Menlo Park, United States
The 151 best Life Sciences companies in Menlo Park, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: GRAIL.
By Riya SenguptaFinancials
151companies tracked
$9.6Bdisclosed funding
1unicorns
106have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × MENLO PARK
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
848kcombined LinkedIn audience
45%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Menlo Park
| # | Company | Disclosed funding | Last round | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | GRAIL Developer of a screening platform for circulating tumor DNA to detect cancer 78Patents top 13%Tech top 16%News top 17%Funding top 20% All 12 signals ▾Patentstop 13% Techtop 16% Newstop 17% Fundingtop 20% Innovationtop 25% Growthtop 36% Markettop 37% Moattop 38% Partnerstop 40% Globaltop 49% Fin. healthbottom 49% Talentbottom 49% Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 78/100 | $2.0B | 8 mo ago | 491 491 → 1,111 (+126%) · sector median +12% | 2016 | WordPressApple iCloud MailGoogle Workspace+24 | 899 patents Liquid biopsy cancer detection via cfDNA methylation and fragment analysis | — |
| 2 | Summit Developer of therapeutics for oncology and rare diseases 22Partners top 31%Funding top 33%Product top 35%News top 37% All 13 signals ▾Partnerstop 31% Fundingtop 33% Producttop 35% Newstop 37% Techtop 45% Growthbottom 43% Moatbottom 43% Marketbottom 42% Talentbottom 41% Globalbottom 37% Patentsbottom 30% Innovationbottom 26% Fin. healthbottom 22% Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $713M | 7 mo ago | 99 | 2003 | WordPress Block EditorWordPressMySQL+18 | 13 patents Digital media submission, processing, and distribution platforms for online content management. | — |
| 3 | 180 Life Sciences Developer of drugs for treating inflammatory diseases | $440M | 10 mo ago | 7 | 2016 | WordPressMySQLPHP+17 | — | — |
| 4 | PacBio Developer of instrument systems and software for real-time sequencing of single-molecules | $342M | 64 mo ago | 649 649 → 589 (-9%) · sector median +12% | 2004 | WordPress Block EditorWordPressMySQL+42 | — | — |
| 5 | ReCode Therapeutics Developer of precision medicines for treating lung related diseases 67Funding top 17%Talent top 28%Moat top 31%Market top 42% All 7 signals ▾Fundingtop 17% Talenttop 28% Moattop 31% Markettop 42% Newstop 45% Techtop 48% Globalbottom 39% Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $342M | 8 mo ago | 105 | 2015 | WordPressApple iCloud MailMicrosoft 365+28 | — | — |
| 6 | Earlens Corporation Provider of hearing aids for people with less hearing power 62Funding top 17%Moat top 19%Tech top 27%Patents top 31% All 10 signals ▾Fundingtop 17% Moattop 19% Techtop 27% Patentstop 31% Innovationtop 36% Talenttop 38% Markettop 49% Globalbottom 47% Growthbottom 39% Newsbottom 21% Funding: Raised $326M across 15 rounds · 15 rounds over 16 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 362 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $326M | 16 mo ago | 129 129 → 111 (-14%) · sector median +12% | 2005 | WordPressSentryApple iCloud Mail+49 | 362 patents Advanced contact hearing aids and acoustic signal processing for ear canal devices | — |
| 7 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | 66 | 2016 | WordPressApple iCloud MailGoogle Workspace+29 | — | 1 expansion |
| 8 | Evidation Real-world health data insights for better healthcare decisions and research 72Funding top 20%Customers top 27%Tech top 31%Moat top 31% All 10 signals ▾Fundingtop 20% Customerstop 27% Techtop 31% Moattop 31% Producttop 36% Talenttop 38% Growthtop 41% Markettop 43% Globalbottom 37% Newsbottom 22% Funding: Raised $259M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) Customers: App rating 4.2★ (20,400 reviews) · Review volume +3% in 6 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $259M | 15 mo ago | 196 196 → 101 (-48%) · sector median +12% | 2012 | WebflowApple iCloud MailGoogle Workspace+18 | — | — |
| 9 | Hexagon Bio Provider of bioinformatics tools for the analysis of microbial genomic sequencing data | $206M | 44 mo ago | 34 34 → 75 (+121%) · sector median +12% | 2017 | WordPressApple iCloud MailGoogle Workspace+17 | — | — |
| 10 | Sudo Biosciences Developer of therapeutics for immune-mediated inflammatory conditions | $183M | 28 mo ago | 11 | 2020 | — | — | — |
| 11 | Alladapt Developer of therapeutics for treating food allergies | $179M | 45 mo ago | 19 | 2018 | — | — | — |
| 12 | Adicet Bio Developer of immune cell therapeutic solutions for the treatment of cancer | $156M | 64 mo ago | 86 | 2014 | DrupalApple iCloud MailPHP+18 | — | — |
| 13 | Nevro Provider of high-frequency spinal cord stimulation implants | $154M | 74 mo ago | 1,215 1,215 → 903 (-26%) · sector median +12% | 2006 | Apple iCloud MailQ4MediaElement.js+20 | 786 patents Optimized spinal cord neurostimulation devices for pain relief with efficient battery use | 2 launchs · 1 partnership |
| 14 | Tricida Therapeutics for complications of Chronic Kidney Disease (CKD) | $153M | 86 mo ago | 26 | 2013 | — | 221 patents Oral proton-binding polymer formulations for treating acid‑base and metabolic acidosis disorders | — |
| 15 | Clear Labs Provider of food safety technologies for the identification of pathogens 60Patents top 19%Funding top 22%Innovation top 28%Moat top 28% All 10 signals ▾Patentstop 19% Fundingtop 22% Innovationtop 28% Moattop 28% Growthtop 32% Talenttop 41% Globalbottom 44% Marketbottom 40% Techbottom 33% Newsbottom 21% Patents: 79 patents matched (strict assignee match) · 40 filings since 2022 vs 25 in 2017-21 Funding: Raised $141M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $141M | 18 mo ago | 55 55 → 85 (+55%) · sector median +12% | 2014 | WordPressApple iCloud MailGoogle Workspace+16 | 79 patents Automated liquid handling and cartridge systems for nucleic‑acid sequencing sample preparation | — |
| 16 | CardioKinetix Implant for heart failure | $137M | 138 mo ago | 23 | 2003 | — | 142 patents Implantable cardiac devices for ventricular partitioning, sealing, and delivery systems. | — |
| 17 | Artera AI-derived prognostic biomarker test for cancer detection | $135M | 28 mo ago | 90 90 → 151 (+68%) · sector median +12% | 2021 | WordPressMySQLPHP+27 | 11 patents AI-powered cancer therapy selection and digital pathology analysis using deep learning. | 1 job opening · 1 launch · 1 partnership |
| 18 | Sight Sciences Developer of surgical systems for the treatment of ophthalmological diseases | $129M | 66 mo ago | 204 204 → 233 (+14%) · sector median +12% | 2006 | WordPressMySQLPHP+31 | 219 patents Ocular drug delivery devices and intraocular implant technologies for eye treatment | — |
| 19 | Antiva Biosciences Developer of therapeutic drugs for sexually transmitted diseases | $125M | 37 mo ago | 21 | 2012 | PHPGSAPApache HTTP Server+7 | — | — |
| 20 | Velomedix Provider of therapeutic hypothermia during ischemic or inflammatory attacks | $123M | 173 mo ago | — | 2015 | RubyVideoJSRuby on Rails+16 | — | — |
| 21 | Endovascular Engineering Provider of mechanical thrombectomy technologies to treat venous thromboembolism 48Funding top 18%Growth top 30%Talent top 38%News top 47% All 8 signals ▾Fundingtop 18% Growthtop 30% Talenttop 38% Newstop 47% Moatbottom 48% Globalbottom 38% Marketbottom 36% Techbottom 30% Funding: Raised $122M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $122M | 2 mo ago | 19 | 2019 | WordPressApple iCloud MailMicrosoft 365+17 | — | 3 job openings · 1 internship |
| 22 | Transcend Medical Glaucoma intervention devices | $122M | 137 mo ago | 20 | 2006 | — | — | — |
| 23 | Mirum Pharmaceuticals Developer of small molecule based therapeutics to treat rare diseases 82Funding top 17%Patents top 18%Innovation top 23%Product top 28% All 12 signals ▾Fundingtop 17% Patentstop 18% Innovationtop 23% Producttop 28% Growthtop 30% Fin. healthtop 31% Markettop 33% Moattop 35% Newstop 36% Techtop 45% Talentbottom 49% Globalbottom 47% Funding: Raised $120M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Patents: 135 patents matched (strict assignee match) · 115 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 4 mo ago | 196 196 → 465 (+137%) · sector median +12% | 2018 | WordPressMySQLPHP+18 | 135 patents IBAT inhibitor drugs for treating cholestasis and pediatric liver disease | — |
| 24 | Deepcell AI-powered single cell classification and isolation technology for clinical research | $118M | 44 mo ago | 94 | 2017 | — | 41 patents Patents concentrated in transport & manufacturing processes | — |
| 25 | Spinal Modulation Neurostimulator for treatment of intractable lower limb pain | $104M | 156 mo ago | 76 | 2004 | — | 207 patents Spinal cord stimulation hardware minimizing lead migration and optimizing stimulation parameters. | — |
| 26 | PellePharm Biotechnology company pioneering precision medicine for rare dermatological conditions | $102M | 90 mo ago | 8 | 2012 | — | 23 patents Topical delivery systems for hedgehog pathway inhibitor drugs in dermatology. | — |
| 27 | Allay Therapeutics Developer of drugs for post-surgical pain management 42Funding top 18%Moat top 39%Market bottom 44%Global bottom 38% All 5 signals ▾Fundingtop 18% Moattop 39% Marketbottom 44% Globalbottom 38% Newsbottom 21% Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $102M | 12 mo ago | 50 | 2017 | — | — | — |
| 28 | Delix Therapeutics Developer of therapeutic solutions for the treatment of multiple neurological disorders | $100M | 24 mo ago | 7 | 2019 | PrismicVimeoReact+9 | — | — |
| 29 | Credence MedSystems Developer of smart devices for drug delivery | $100M | 18 mo ago | 20 20 → 13 (-35%) · sector median +12% | 2011 | WordPressMySQLPHP+19 | 262 patents Safety-engineered syringes and multi-site micro-dose injection devices. | — |
| 30 | AN2 Therapeutics Developer of drugs for treating infectious disease 45Funding top 19%Talent top 38%Moat top 48%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 38% Moattop 48% Marketbottom 42% Globalbottom 32% Newsbottom 24% Funding: Raised $92.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $92M | 3 mo ago | 35 35 → 37 (+6%) · sector median +12% | 2017 | — | — | — |
| 31 | Phathom Pharmaceuticals Developer of therapies for treating gastrointestinal diseases | $90M | 85 mo ago | 113 | 2019 | DrupalApple iCloud MailPHP+35 | — | 1 award |
| 32 | Octave Bioscience Provider of AI-based molecular diagnostic tools for neurodegenrative diseases 69Funding top 20%Innovation top 32%Growth top 35%Product top 35% All 11 signals ▾Fundingtop 20% Innovationtop 32% Growthtop 35% Producttop 35% Talenttop 38% Moattop 39% AItop 45% Techtop 48% Marketbottom 43% Newsbottom 42% Globalbottom 38% Funding: Raised $88.0M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) Innovation: 2 product lines · Deep-tech classification: Tech Hardware rank vs industry peers · Fliar Intelligence Index 69/100 | $88M | 9 mo ago | 90 | 2014 | WordPressApple iCloud MailGoogle Workspace+26 | — | 1 launch |
| 33 | Personalis Provider of genomic sequencing and diagnosis software for the healthcare industry | $87M | 18 mo ago | 310 310 → 402 (+30%) · sector median +12% | 2011 | WordPressMySQLMariaDB+22 | 83 patents Clinical genomics data analysis pipelines for cancer, mosaicism, methylation and multi-species NGS | — |
| 34 | Intersect ENT Developer of drug releasing implant to treat sinusitis | $77M | 73 mo ago | 371 | 2003 | — | — | — |
| 35 | Ceterix Suture passer for orthopedic srugery | $74M | 114 mo ago | 63 | 2010 | — | — | — |
| 36 | Strateos Provider of cloud based platform provides data driven information for biotech research | $73M | 60 mo ago | 147 | 2019 | — | 15 patents Remote laboratory automation platforms for managing and executing biological experiment workflows | — |
| 37 | Enable Medicine Provider of drug research & development services for pharmaceutical sector | $64M | 50 mo ago | 51 | 2019 | WebflowApple iCloud MailGoogle Workspace+17 | — | — |
| 38 | Adverum Biotechnologies Developer of gene therapy based therapies for wet age-related macular degeneration & ophthalmologic disorders | $61M | 28 mo ago | 123 123 → 138 (+12%) · sector median +12% | 2006 | WordPressApple iCloud MailMicrosoft 365+21 | 319 patents Gene‑therapy AAV vectors for treating ocular neovascular and inflammatory eye diseases | — |
| 39 | Tusker Medical Online gaming platform offering diverse slot games with high RTP | $48M | 83 mo ago | 26 | 2016 | — | 159 patents Otic drug delivery via iontophoresis and intraoperative medical visualization systems | — |
| 40 | Farapulse Advanced cardiac ablation solutions for atrial fibrillation treatment | $36M | 63 mo ago | 45 | 2014 | Adobe Experience ManagerJavaGraphQL+19 | 129 patents Pulsed electric field electroporation devices for minimally invasive cardiac, renal, and esophageal ablation | — |
| 41 | Jupiter Endovascular Developer of minimally invasive medical devices for endovascular intervention | $21M | 8 mo ago | — | 2024 | WordPressApple iCloud MailGoogle Workspace+17 | — | — |
| 42 | Mural Health Provider of clinical trial technology platform for participants | $21M | 26 mo ago | 17 | 2022 | WebflowSentryApple iCloud Mail+19 | — | — |
| 43 | Combangio Developer of biotherapeutics to treat vision-threatening diseases | $15M | 37 mo ago | 3 | 2014 | — | 57 patents Lyophilized mesenchymal stem cell secretome therapeutics and cellular fibronectin biomaterials | — |
| 44 | ResistanceBio Developer of therapeutics for treatment-resistant cancer | $13M | 28 mo ago | — | 2016 | — | — | — |
| 45 | CyteSi Developer of biomedical laboratory automation technology for life science research 53Talent top 27%Tech top 31%Partners top 33%Market top 36% All 8 signals ▾Talenttop 27% Techtop 31% Partnerstop 33% Markettop 36% Newsbottom 45% Growthbottom 32% Fundingbottom 31% Globalbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Tech: 41 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 53/100 | $12M | 25 mo ago | — | 2020 | DrupalApple iCloud MailMicrosoft 365+15 | — | 6 job openings |
| 46 | IncellDx Single-cell diagnostics company advancing precision medicine through innovative technology | $9M | 23 mo ago | 24 | 2009 | — | 96 patents Molecular diagnostics and personalized therapeutics for viral and post‑infectious diseases | — |
| 47 | Tivic Health Developer of a bioelectronic medical device for the treatment of sinusitis | $8M | 6 mo ago | 16 16 → 13 (-19%) · sector median +12% | 2016 | Cart FunctionalityShopifySentry+30 | — | — |
| 48 | Aecor Bio Developer of peptide therapies targeting treatment resistance and restoring cellular micro-environments | $3M | 10 mo ago | — | 2023 | — | — | — |
| 49 | MedaSystems Cloud-based clinical decision making | $2M | 15 mo ago | 10 | 2020 | — | — | — |
| 50 | Attune Neurosciences Developer of the device for neurostimulation | $1M | 17 mo ago | 7 | 2019 | Cart FunctionalitySquarespace CommerceSquarespace+15 | 20 patents Non‑invasive ultrasound neuromodulation devices for precise brain network stimulation | — |
Top 12 Life Sciences companies in Menlo Park
#1
Public · Menlo Park, California · founded 2016 · 491 employees$2Braised▾
Public · Menlo Park, California · founded 2016 · 491 employees
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Patents
top 13%Tech
top 16%News
top 17%Funding
top 20%Innovation
top 25%Growth
top 36%Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 · Latest publication 2026
Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront · Devops: Nginx
News: 11 BI events in 12 mo (of 75 tracked, 14 types) · +83% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 113k LinkedIn followers — 13.3% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$325M
- Nov 2019Series D$390M
- May 2018Series C$300M
- Jun 2017Series B—
Founders & team
Investors
PSP Investments, CPP Investments, Illumina, Arch Venture Partners, Johnson & Johnson Innovation, McKesson Ventures
Tech stack
Amazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApolloApple Icloud Mail
#2
Series C · Menlo Park, California · founded 2019 · 19 employees$122.3Mraised▾
Series C · Menlo Park, California · founded 2019 · 19 employees
Provider of mechanical thrombectomy technologies to treat venous thromboembolism. It offers Hēlo Thrombectomy System designed to remove clots efficiently using a dual-action mechanism. It combines aspiration and mechanical clot disruption with a small profile catheter that expands for high-performance clot engagement.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 18%Growth
top 30%Talent
top 38%News
top 47%Moat
bottom 48%Global
bottom 38%Funding: Raised $122M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series C (Apr 2026)
Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Area Sales Manager, Director of Finance & Accounting
Funding rounds
- Apr 2026Series C$80M
- Feb 2025Series B$42M
- Apr 2022Seed—
- Sep 2021Grant (prize money)$298.2K
Founders & team
Investors
Cordis, Sante, 415 CAPITAL, Panakes Partners, S3 Ventures, M&L Healthcare
Tech stack
Apache Http ServerApple Icloud MailBluehostBootstrapGoogle AnalyticsGsap
#3
Public · Menlo Park, California · founded 2003 · 99 employees$713Mraised▾
Public · Menlo Park, California · founded 2003 · 99 employees
Developer of therapeutics for oncology and rare diseases. It offers Ivonescimab which combines the effects of immunotherapy via a blockade of PD-1 with the anti-VEGF effect for the treatment of non-small cell lung cancer.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Partners
top 31%Funding
top 33%Product
top 35%News
top 37%Tech
top 45%Growth
bottom 43%Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Post IPO (Oct 2025)
Product: 0 product launch events in 12 mo, 1 the year before · Company stage: Public
Audience (LinkedIn): 58k LinkedIn followers — 6.9% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$228M
- Sep 2024Post IPO$235M
- Jun 2024Post IPO$200M
- Nov 2020Post IPO$50M
Founders & team
Investors
Akeso
Tech stack
CloudflareFancyboxGodaddyGoogle Font ApiHstsJquery
#4
Orca Bio 🦄Series F · Menlo Park, California · founded 2016 · 66 employees$300Mraised▾
Orca Bio 🦄
Series F · Menlo Park, California · founded 2016 · 66 employees
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 18%Growth
top 26%Moat
top 26%Talent
top 38%Tech
top 40%Market
top 42%Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series F (Jan 2026)
Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 9/10 · Unicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 2.9% of this cohort's audience · 158 engagements/post (3.2× cohort median)
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series F$250M
- Nov 2019Series D$192M
Founders & team
Investors
Lightspeed Venture Partners, 8VC, DCVC, ND Capital, IMRF, Kaiser Permanente
Tech stack
Amazon Web ServicesApple Icloud MailBackbone.JsBrizy WordpressBunnyBunny Fonts
#5
Public · Menlo Park, California · founded 2017 · 35 employees$92Mraised▾
Public · Menlo Park, California · founded 2017 · 35 employees
Developer of drugs for treating infectious disease. The company is developing novel small molecule therapeutics, designing and executing clinical trials on experimental treatments, and navigating the regulatory approval process for new medicines.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 19%Talent
top 38%Moat
top 48%Market
bottom 42%Global
bottom 32%News
bottom 24%Funding: Raised $92.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Post IPO (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. GSK for TB) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$40M
- Jan 2022Series B$80M
- Nov 2019Series A$12M
Founders & team
Investors
Mountain Group Partners, Adjuvant Capital, Brii Biosciences, BioRock Ventures, RA Capital Management, BVF Partners
#6
Series B · Menlo Park, California · founded 2015 · 105 employees$342Mraised▾
Series B · Menlo Park, California · founded 2015 · 105 employees
Developer of precision medicines for treating lung-related diseases. The pipeline includes lead programs which includes RCT1100 an inhaled mRNA-based investigational therapy for primary ciliary dyskinesia caused by mutations in the DNAI1 gene and RCT2100 is an inhaled mRNA-based investigational therapy for cystic fibrosis. It has proprietary non-viral lipid nanoparticle platform that enables the delivery of a variety of payloads, and organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Talent
top 28%Moat
top 31%Market
top 42%News
top 45%Tech
top 48%Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) · Last round Series B (Sep 2025)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Funding rounds
- Sep 2025Series B$29M
- Sep 2023Series B$50M
- Jan 2023Series B$10M
- Jun 2022Series B$120M
Founders & team
Investors
Orbimed, Colt Ventures, Vida Ventures, Cystic Fibrosis Foundation, Solasta Ventures, Bioluminescence Ventures
#7
Public · Menlo Park, California · founded 2018 · 196 employees$120Mraised▾
Public · Menlo Park, California · founded 2018 · 196 employees
Developer of small molecule based therapeutics to treat rare diseases. The company's lead product candidate Maralixibat inhibits a carrier protein called apical sodium-dependent bile acid transporter for reducing systemic levels of bile acids. It is used for the treatment of both Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis. The other product of the company Volixibat is used for the treatment of adult cholestasis.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 17%Patents
top 18%Innovation
top 23%Product
top 28%Growth
top 30%Fin. health
top 31%Funding: Raised $120M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Post IPO (Jan 2026)
Patents: 135 patents matched (strict assignee match) · 115 filings since 2022 vs 20 in 2017-21 · Latest publication 2026
Innovation: 135 patents (top 21% of patent-holders) · 115 filings since 2022 vs 20 in 2017-21
Audience (LinkedIn): 47k LinkedIn followers — 5.5% of this cohort's audience
Funding rounds
- Jan 2026Post IPO$68.5M
- Dec 2020Post IPO$10M
- Nov 2018Series A$120M
Founders & team
Investors
New Enterprise Associates, Deerfield, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, Rock Springs Capital
Tech stack
CloudflareCloudflare Bot ManagementCookieyesDocusignGodaddyGoogle Analytics
#8
Public · Menlo Park, California · founded 2016 · 7 employees$439.6Mraised▾
Public · Menlo Park, California · founded 2016 · 7 employees
Developer of drugs for treating inflammatory diseases. The company has developed Fibrosis & Anti TNF that helps in treating POCD, NACH, Dupuytren's contracture, frozen shoulder, and others. It also provides SCAs that are in the clinical stage and helps in treating diseases like chronic pain, early arthritis, and others. Its drug candidate q7nAChr provides solutions for smoking cessation-induced ulcerative colitis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 684 LinkedIn followers
Funding rounds
- Jul 2025Post IPO$425M
- Dec 2024Post IPO$2.9M
- Feb 2021Post IPO$11.7M
Investors
Electric Capital, Polychain, GSR, Omicron Technologies, Harbour Island
#9
Series C · Menlo Park, California · founded 2014 · 90 employees$88Mraised▾
Series C · Menlo Park, California · founded 2014 · 90 employees
Provider of AI-based molecular diagnostic tools for neurodegenerative diseases. The company has developed the first blood test to measure disease activity at the biology level. The platform will captures data using sensors, wearables & mobile tools to identify changes in disease status and optimize images adding quantitation, serial trends.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 20%Innovation
top 32%Growth
top 35%Product
top 35%Talent
top 38%Moat
top 39%Funding: Raised $88.0M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) · Last round Conventional Debt (Sep 2025)
Innovation: 2 product lines · Deep-tech classification: Tech Hardware
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 30k LinkedIn followers — 3.6% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Sep 2025Conventional Debt$15.5M
- Mar 2025Series C$35.6M
- Nov 2023Grant (prize money)$10M
- Sep 2023Series B$7M
Founders & team
Investors
Novartis, Intermountain Ventures, BVF, Echo Health Ventures, Northpond Ventures, Deerfield
Tech stack
AcuityadsAmazon SesAmazon Web ServicesApple Icloud MailCdnjsCloudflare
#10
Series E · Menlo Park, California · founded 2005 · 129 employees$326.3Mraised▾
Series E · Menlo Park, California · founded 2005 · 129 employees
Provider of hearing aids for people with less hearing power. It develops a light-driven hearing aid that uses light to transmit sound. The device uses light and a small lens placed on the user's eardrum that directly activates your natural hearing system.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 17%Moat
top 19%Tech
top 27%Patents
top 31%Innovation
top 36%Talent
top 38%Funding: Raised $326M across 15 rounds · 15 rounds over 16 yrs (0.9/yr) · Last round Series E (Feb 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 362 patents · Soonicorn
Tech: 57 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services · Observability: Microsoft Clarity, Sentry
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 5 hiring posts in 12 mo (public) · hiring: Remote Diagnostic Audiologist, Audiology Technician
Funding rounds
- Feb 2025Series E$8M
- Apr 2024Series E$18.8M
- Jan 2021Series E$33.2M
- Apr 2020Series D$12.2M
Founders & team
Investors
CRG, Vertex Ventures HC, SightLine Partners, New Enterprise Associates, Aisling Capital, Lightstone Ventures
Tech stack
AccessibeActivecampaignAdrollAdroll Cmp SystemAmazon SesAmazon Web Services
#11
Series E · Menlo Park, California · founded 2012 · 196 employees$259.2Mraised▾
Series E · Menlo Park, California · founded 2012 · 196 employees
Real-world health data insights for better healthcare decisions and research. The company connects directly with individuals to gather real-world health data, providing valuable insights for healthcare and research. They empower individuals to contribute their health data and benefit from its value, fostering a community focused on improving health outcomes. The company partners with organizations across life sciences, healthcare, government, and research to drive discoveries and advance healthcare. They offer solutions for patient insights, recruitment, real-world studies, and data analysis, leveraging diverse data sources like electronic health records, patient-reported outcomes, and data from devices. The company is committed to building trust and transparency, ensuring individuals have control over their data and are rewarded for engaging with their health. Their platform facilitates research and programs across various health conditions, contributing to a deeper understanding of health and disease.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 20%Customers
top 27%Tech
top 31%Moat
top 31%Product
top 36%Talent
top 38%Funding: Raised $259M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Grant (prize money) (Mar 2025)
Customers: App rating 4.2★ (20,400 reviews) · Review volume +3% in 6 mo · Marquee-customer mentions: top 17% of tracked companies
Tech: 34 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services · Devops: Envoy
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$304K
- Mar 2021Series E$153M
- Jul 2020Series D$45M
- Aug 2018Series C$30M
Founders & team
Investors
General Electric, Sanofi Ventures, B Capital, McKesson, OMERS, Rock Health
Tech stack
Amazon CloudfrontAmazon Web ServicesApple Icloud MailApple Sign-InCloudflareCloudflare Bot Management
#12
Series D · Menlo Park, California · founded 2017 · 50 employees$101.9Mraised▾
Series D · Menlo Park, California · founded 2017 · 50 employees
Developer of drugs for post-surgical pain management. The company's proprietary technology platform combines non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site. The company's lead candidate is ATX-101 for post surgical knee rehabilitation. Other candidates include ATX-201 and ATX-301 injectables for on-demand delivery.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 18%Moat
top 39%Market
bottom 44%Global
bottom 38%News
bottom 21%Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Venture Debt (Jun 2025)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Market: 50 employees
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jun 2025Venture Debt—
- Jan 2025Series D$57.5M
- Dec 2022Series D—
- Sep 2021Series C$86.9M
Investors
Arboretum Ventures, New Enterprise Associates, Temasek, Pavilion Capital Partners, Vertex Ventures HC, Vertex Growth
Funding & investor landscape
$9.6Btotal disclosed funding
110companies funded
392disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Bob Ragusa
Chief Executive Officer · GRAIL
Mike Rosenthal
Co-Founder & Chief Operating Officer · Endovascular Engineering
Dan Rose
CEO · Endovascular Engineering
Maky Zanganeh
CEO · Summit
Jeroen Bekaert
Co-Founder & COO · Orca Bio
Ivan Dimov
Co-Founder & Co-CEO · Orca Bio
Eric Easom
Co-Founder & CEO & President · AN2 Therapeutics
Michael Alley
Co-Founder · AN2 Therapeutics
Daniel Siegwart
Co-Founder · ReCode Therapeutics
Philip Thomas
Co-Founder · ReCode Therapeutics
Christopher Peetz
CEO · Mirum Pharmaceuticals
William Hagstrom
Co-Founder & CEO · Octave Bioscience
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged from 33 to 164 papers, making it the dominant rising sub-topic in a shrinking segment.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements each jumped from 3 to 62 papers as the advancements segment grew from 29% to 35% field-share.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled from 15 to 45 while integrated pest management newly emerged, signaling broadening biosafety scrutiny.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
How many Life Sciences companies are there in Menlo Park, United States?
Radar tracks 151 indexable Life Sciences companies headquartered in Menlo Park, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Menlo Park, United States?
The Life Sciences companies in Menlo Park, United States on this list have raised a combined $9.6B in disclosed equity funding across 110 funded companies.
Which is the highest-funded Life Sciences company in Menlo Park, United States?
GRAIL is the highest-funded Life Sciences company in Menlo Park, United States, with $2B in disclosed equity funding.
How many Life Sciences companies in Menlo Park, United States are funded?
110 of the 151 Life Sciences companies in Menlo Park, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Menlo Park, United States?
1 Life Sciences company in Menlo Park, United States on this list is valued at $1B or more.
Who are the top investors in Menlo Park, United States Life Sciences companies?
The most active investors in Menlo Park, United States Life Sciences companies on this list include HHS, New Enterprise Associates, Vivo Capital, Aisling Capital, Deerfield.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.